2024-11-22 I-Mab Biopharma HaiPress

The 36th Annual Healthcare Conference will be held in New York,December 3-5,2024
ROCKVILLE,Md.,Nov. 21,2024 -- I-Mab (NASDAQ: IMAB,the "Company"),a U.S.-based global biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on December 4,2024.
Piper Sandler 36th Annual Healthcare Conference Presentation Details
Presentation Time
Wednesday,December 4 at4:30 p.m. ET
Presenters
Sean Fu,PhD,MBA,Chief Executive Officer
Phillip Dennis,MD,Chief Medical Officer
Webcast link
Here
Meetings
One-on-one and small group meetings:December 3 – 4,2024
Management
Participants
Sean Fu,Chief Executive Officer
Joseph Skelton,Chief Financial Officer
Phillip Dennis,Chief Medical Officer
Tyler Ehler,Senior Director,Investor Relations
The webcast will also be available under "Event Calendar" onI-Mab'sIR website
athttps://ir.i-mabbiopharma.com/
For more information,please contact your Piper Sandler representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based,global biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey. For more information,please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information,please contact:
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com
CGTN: How China embraces the world with open arms, boosts development for all
Cangxi County Holds 2026 New Year's Cultural Performance for the Public
The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
©copyright 2009-2020 Singapore Info Map